Pharma & Biotech Deals 2018 – more to come in 2019

In 2018, each month PharmaCompass published PharmaFlow — a compilation of all the major deals in the industry that took place in the preceding month. We begin 2019 with our annual compilation of the deals of 2018, packed with some exciting trends for the future.

Undoubtedly, 2018 was a landmark year for dealmaking in the pharmaceutical and biotech sector. As per our analysis, each month of the year saw over 100 deals in the sector.

It was also a big year for venture capital investments. Data shows annual venture capital investments across all sectors surpassed US$10 billion for the first time in 2018, since the dot-com era of 2000. The pharma and biotech sector, in particular, saw approximately 700 venture capital deals, reaching US$ 17 billion in value — making 2018 the biggest year for venture capital deals in the sector.

As the future strategy of major pharmaceutical companies came into question and the drug pricing debate dominated news headlines, companies like Novartis, Sanofi, GSK and Takeda announced deals that will fundamentally transform the way they do business in the future. Read full article and access the numbers here